organization · Reporting owner

MonoLine RX, L.P.

Disclosed activity across 1 company

Tapewire entity: 141267
SEC CIK: 0001410626

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Aquestive Therapeutics, Inc.AQST · Entity 5276	10% owner	March 12, 2021	March 16, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Aquestive Therapeutics, Inc.

Report date March 12, 2021 · Filed March 16, 2021

Jointly reported with BRATTON DOUGLAS K, MonoLine Partners, L.P., MonoLine RX II, L.P., MonoLine RX III, L.P., MonoSol Rx Genpar, L.P., MRX Partners, LLC, Bratton Capital Inc., Bratton Capital Management, L.P.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	1,688,639	Reported balance After 2021-03-12 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2021-03-12 · Other · Disposed 524,675 · Balance 1,688,639 F1: Pro rata distribution for no consideration of shares of common stock of the Issuer ("Common Stock") by the applicable MonoLine Entity or Monosol (each as defined below), as indicated in the respective footnotes. F2: These securities are owned, as indicated, by MonoLine Partners, L.P. ("MonoLine"), MRX Partners, LLC ("MRX Partners"), MonoLine Rx, L.P. ("Monoline Rx"), MonoLine Rx II, L.P. ("Monoline II"), and MonoLine Rx III, L.P. ("Monoline III"), respectively. Monoline, MRX Partners, Monoline Rx, Monoline II, and Monoline III are referred to herein collectively as the "Monoline Entities" and each individually a "Monoline Entity". Bratton Capital Management, L.P. ("Bratton Capital Management") is the manager of MRX Partners and general partner of each of the other Monoline Entities. Bratton Capital, Inc. ("Bratton") is the general partner of Bratton Capital Management. The Reporting Person, Douglas K. Bratton, is the sole director and President of Bratton and has voting and investment power over all shares held by the Monoline Entities. F3: Bratton Capital Management, Bratton, and Mr. Bratton may each be deemed to own beneficially all shares owned by the Monoline Entities, and Bratton and Mr. Bratton may be deemed to beneficially own all shares held by Monosol. Each such entity and Mr. Bratton disclaims beneficial ownership of the reported securities except to the extent of its or his respective pecuniary interest therein. F4: These securities are beneficially owned by Monoline Rx.
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	3,468,747	Reported balance After 2021-03-12 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2021-03-12 · Other · Disposed 564,160 · Balance 3,468,747 F1: Pro rata distribution for no consideration of shares of common stock of the Issuer ("Common Stock") by the applicable MonoLine Entity or Monosol (each as defined below), as indicated in the respective footnotes. F2: These securities are owned, as indicated, by MonoLine Partners, L.P. ("MonoLine"), MRX Partners, LLC ("MRX Partners"), MonoLine Rx, L.P. ("Monoline Rx"), MonoLine Rx II, L.P. ("Monoline II"), and MonoLine Rx III, L.P. ("Monoline III"), respectively. Monoline, MRX Partners, Monoline Rx, Monoline II, and Monoline III are referred to herein collectively as the "Monoline Entities" and each individually a "Monoline Entity". Bratton Capital Management, L.P. ("Bratton Capital Management") is the manager of MRX Partners and general partner of each of the other Monoline Entities. Bratton Capital, Inc. ("Bratton") is the general partner of Bratton Capital Management. The Reporting Person, Douglas K. Bratton, is the sole director and President of Bratton and has voting and investment power over all shares held by the Monoline Entities. F3: Bratton Capital Management, Bratton, and Mr. Bratton may each be deemed to own beneficially all shares owned by the Monoline Entities, and Bratton and Mr. Bratton may be deemed to beneficially own all shares held by Monosol. Each such entity and Mr. Bratton disclaims beneficial ownership of the reported securities except to the extent of its or his respective pecuniary interest therein. F5: These securities are beneficially owned by Monoline II.
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	2,657,943	Reported balance After 2021-03-12 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2021-03-12 · Other · Disposed 97,598 · Balance 2,657,943 F1: Pro rata distribution for no consideration of shares of common stock of the Issuer ("Common Stock") by the applicable MonoLine Entity or Monosol (each as defined below), as indicated in the respective footnotes. F2: These securities are owned, as indicated, by MonoLine Partners, L.P. ("MonoLine"), MRX Partners, LLC ("MRX Partners"), MonoLine Rx, L.P. ("Monoline Rx"), MonoLine Rx II, L.P. ("Monoline II"), and MonoLine Rx III, L.P. ("Monoline III"), respectively. Monoline, MRX Partners, Monoline Rx, Monoline II, and Monoline III are referred to herein collectively as the "Monoline Entities" and each individually a "Monoline Entity". Bratton Capital Management, L.P. ("Bratton Capital Management") is the manager of MRX Partners and general partner of each of the other Monoline Entities. Bratton Capital, Inc. ("Bratton") is the general partner of Bratton Capital Management. The Reporting Person, Douglas K. Bratton, is the sole director and President of Bratton and has voting and investment power over all shares held by the Monoline Entities. F3: Bratton Capital Management, Bratton, and Mr. Bratton may each be deemed to own beneficially all shares owned by the Monoline Entities, and Bratton and Mr. Bratton may be deemed to beneficially own all shares held by Monosol. Each such entity and Mr. Bratton disclaims beneficial ownership of the reported securities except to the extent of its or his respective pecuniary interest therein. F6: These securities are beneficially owned by Monoline III.
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	47,051	Reported balance After 2021-03-12 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2021-03-12 · Other · Disposed 40,404 · Balance 47,051 F1: Pro rata distribution for no consideration of shares of common stock of the Issuer ("Common Stock") by the applicable MonoLine Entity or Monosol (each as defined below), as indicated in the respective footnotes. F3: Bratton Capital Management, Bratton, and Mr. Bratton may each be deemed to own beneficially all shares owned by the Monoline Entities, and Bratton and Mr. Bratton may be deemed to beneficially own all shares held by Monosol. Each such entity and Mr. Bratton disclaims beneficial ownership of the reported securities except to the extent of its or his respective pecuniary interest therein. F7: These securities are beneficially owned by MonoSol Rx Genpar, L.P. ("Monosol"). Bratton is the general partner of Monosol. The Reporting Person, Douglas K. Bratton, is the sole director and President of Bratton and has voting and investment power over all shares held by Monosol.
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	0	Reported balance After 2021-03-12 transaction · row 5 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 5 · 2021-03-12 · Other · Disposed 2,249,077 · Balance 0 F1: Pro rata distribution for no consideration of shares of common stock of the Issuer ("Common Stock") by the applicable MonoLine Entity or Monosol (each as defined below), as indicated in the respective footnotes. F2: These securities are owned, as indicated, by MonoLine Partners, L.P. ("MonoLine"), MRX Partners, LLC ("MRX Partners"), MonoLine Rx, L.P. ("Monoline Rx"), MonoLine Rx II, L.P. ("Monoline II"), and MonoLine Rx III, L.P. ("Monoline III"), respectively. Monoline, MRX Partners, Monoline Rx, Monoline II, and Monoline III are referred to herein collectively as the "Monoline Entities" and each individually a "Monoline Entity". Bratton Capital Management, L.P. ("Bratton Capital Management") is the manager of MRX Partners and general partner of each of the other Monoline Entities. Bratton Capital, Inc. ("Bratton") is the general partner of Bratton Capital Management. The Reporting Person, Douglas K. Bratton, is the sole director and President of Bratton and has voting and investment power over all shares held by the Monoline Entities. F3: Bratton Capital Management, Bratton, and Mr. Bratton may each be deemed to own beneficially all shares owned by the Monoline Entities, and Bratton and Mr. Bratton may be deemed to beneficially own all shares held by Monosol. Each such entity and Mr. Bratton disclaims beneficial ownership of the reported securities except to the extent of its or his respective pecuniary interest therein. F8: These securities are beneficially owned by MRX Partners.
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	1,948,578	Reported balance After 2021-03-12 transaction · row 6 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 6 · 2021-03-12 · Other · Acquired 1,783,578 · Balance 1,948,578 F9: Shares of Common Stock acquired through pro rata distribution for no consideration by MRX Partners. F2: These securities are owned, as indicated, by MonoLine Partners, L.P. ("MonoLine"), MRX Partners, LLC ("MRX Partners"), MonoLine Rx, L.P. ("Monoline Rx"), MonoLine Rx II, L.P. ("Monoline II"), and MonoLine Rx III, L.P. ("Monoline III"), respectively. Monoline, MRX Partners, Monoline Rx, Monoline II, and Monoline III are referred to herein collectively as the "Monoline Entities" and each individually a "Monoline Entity". Bratton Capital Management, L.P. ("Bratton Capital Management") is the manager of MRX Partners and general partner of each of the other Monoline Entities. Bratton Capital, Inc. ("Bratton") is the general partner of Bratton Capital Management. The Reporting Person, Douglas K. Bratton, is the sole director and President of Bratton and has voting and investment power over all shares held by the Monoline Entities. F3: Bratton Capital Management, Bratton, and Mr. Bratton may each be deemed to own beneficially all shares owned by the Monoline Entities, and Bratton and Mr. Bratton may be deemed to beneficially own all shares held by Monosol. Each such entity and Mr. Bratton disclaims beneficial ownership of the reported securities except to the extent of its or his respective pecuniary interest therein. F10: These securities are beneficially owned by MonoLine.
Common StockSEC Table I · non-derivative	Direct	12,585	Reported balance After 2021-03-09 transaction · row 7 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 7 · 2021-03-09 · Gift · Disposed 62,500 · Balance 12,585 F11: Gift of shares of Common Stock to charitable organization. F12: Following the transactions reported on this Form 4, the Reporting Persons as listed in this Form 4 are the beneficial owners in the aggregate of 10,060,657 shares of Common Stock for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, representing a 27.8% ownership interest in the Issuer based on total shares outstanding of 36,213,969 as of March 5, 2021, such shares outstanding as reported in the Issuer's Annual Report on Form 10-K for the fiscal year ended December 31, 2020.

Filing footnotes · ownership attribution and instrument terms

F1: Pro rata distribution for no consideration of shares of common stock of the Issuer ("Common Stock") by the applicable MonoLine Entity or Monosol (each as defined below), as indicated in the respective footnotes.

F2: These securities are owned, as indicated, by MonoLine Partners, L.P. ("MonoLine"), MRX Partners, LLC ("MRX Partners"), MonoLine Rx, L.P. ("Monoline Rx"), MonoLine Rx II, L.P. ("Monoline II"), and MonoLine Rx III, L.P. ("Monoline III"), respectively. Monoline, MRX Partners, Monoline Rx, Monoline II, and Monoline III are referred to herein collectively as the "Monoline Entities" and each individually a "Monoline Entity". Bratton Capital Management, L.P. ("Bratton Capital Management") is the manager of MRX Partners and general partner of each of the other Monoline Entities. Bratton Capital, Inc. ("Bratton") is the general partner of Bratton Capital Management. The Reporting Person, Douglas K. Bratton, is the sole director and President of Bratton and has voting and investment power over all shares held by the Monoline Entities.

F3: Bratton Capital Management, Bratton, and Mr. Bratton may each be deemed to own beneficially all shares owned by the Monoline Entities, and Bratton and Mr. Bratton may be deemed to beneficially own all shares held by Monosol. Each such entity and Mr. Bratton disclaims beneficial ownership of the reported securities except to the extent of its or his respective pecuniary interest therein.

F4: These securities are beneficially owned by Monoline Rx.

F5: These securities are beneficially owned by Monoline II.

F6: These securities are beneficially owned by Monoline III.

F7: These securities are beneficially owned by MonoSol Rx Genpar, L.P. ("Monosol"). Bratton is the general partner of Monosol. The Reporting Person, Douglas K. Bratton, is the sole director and President of Bratton and has voting and investment power over all shares held by Monosol.

F8: These securities are beneficially owned by MRX Partners.

F9: Shares of Common Stock acquired through pro rata distribution for no consideration by MRX Partners.

F10: These securities are beneficially owned by MonoLine.

F11: Gift of shares of Common Stock to charitable organization.

F12: Following the transactions reported on this Form 4, the Reporting Persons as listed in this Form 4 are the beneficial owners in the aggregate of 10,060,657 shares of Common Stock for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, representing a 27.8% ownership interest in the Issuer based on total shares outstanding of 36,213,969 as of March 5, 2021, such shares outstanding as reported in the Issuer's Annual Report on Form 10-K for the fiscal year ended December 31, 2020.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
March 12, 2021 Filed Mar 16, 2021 20:20 UTC	Aquestive Therapeutics, Inc. AQST · Entity 5276	OtherCommon Stock	1,783,578	$0.00	$0.00	Disclosure SEC source: 0001214659-21-003203 · marketforms-51911.xml · nonDerivative · entry 6 BRATTON DOUGLAS K · CIK 0001281933 · 10% owner MonoLine Partners, L.P. · CIK 0001747211 · 10% owner MonoLine RX, L.P. · CIK 0001410626 · 10% owner MonoLine RX II, L.P. · CIK 0001410625 · 10% owner MonoLine RX III, L.P. · CIK 0001747169 · 10% owner MonoSol Rx Genpar, L.P. · CIK 0001747548 · 10% owner MRX Partners, LLC · CIK 0001746904 · 10% owner Bratton Capital Inc. · CIK 0001723783 · 10% owner Bratton Capital Management, L.P. · CIK 0001723787 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 1,948,578 F9 · kind: Shares of Common Stock acquired through pro rata distribution for no consideration by MRX Partners. F2 · ownership.nature: These securities are owned, as indicated, by MonoLine Partners, L.P. ("MonoLine"), MRX Partners, LLC ("MRX Partners"), MonoLine Rx, L.P. ("Monoline Rx"), MonoLine Rx II, L.P. ("Monoline II"), and MonoLine Rx III, L.P. ("Monoline III"), respectively. Monoline, MRX Partners, Monoline Rx, Monoline II, and Monoline III are referred to herein collectively as the "Monoline Entities" and each individually a "Monoline Entity". Bratton Capital Management, L.P. ("Bratton Capital Management") is the manager of MRX Partners and general partner of each of the other Monoline Entities. Bratton Capital, Inc. ("Bratton") is the general partner of Bratton Capital Management. The Reporting Person, Douglas K. Bratton, is the sole director and President of Bratton and has voting and investment power over all shares held by the Monoline Entities. F3 · ownership.nature: Bratton Capital Management, Bratton, and Mr. Bratton may each be deemed to own beneficially all shares owned by the Monoline Entities, and Bratton and Mr. Bratton may be deemed to beneficially own all shares held by Monosol. Each such entity and Mr. Bratton disclaims beneficial ownership of the reported securities except to the extent of its or his respective pecuniary interest therein. F10 · ownership.nature: These securities are beneficially owned by MonoLine. Read SEC document
March 12, 2021 Filed Mar 16, 2021 20:20 UTC	Aquestive Therapeutics, Inc. AQST · Entity 5276	OtherCommon Stock	2,249,077	$0.00	$0.00	Disclosure SEC source: 0001214659-21-003203 · marketforms-51911.xml · nonDerivative · entry 5 BRATTON DOUGLAS K · CIK 0001281933 · 10% owner MonoLine Partners, L.P. · CIK 0001747211 · 10% owner MonoLine RX, L.P. · CIK 0001410626 · 10% owner MonoLine RX II, L.P. · CIK 0001410625 · 10% owner MonoLine RX III, L.P. · CIK 0001747169 · 10% owner MonoSol Rx Genpar, L.P. · CIK 0001747548 · 10% owner MRX Partners, LLC · CIK 0001746904 · 10% owner Bratton Capital Inc. · CIK 0001723783 · 10% owner Bratton Capital Management, L.P. · CIK 0001723787 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 F1 · kind: Pro rata distribution for no consideration of shares of common stock of the Issuer ("Common Stock") by the applicable MonoLine Entity or Monosol (each as defined below), as indicated in the respective footnotes. F2 · ownership.nature: These securities are owned, as indicated, by MonoLine Partners, L.P. ("MonoLine"), MRX Partners, LLC ("MRX Partners"), MonoLine Rx, L.P. ("Monoline Rx"), MonoLine Rx II, L.P. ("Monoline II"), and MonoLine Rx III, L.P. ("Monoline III"), respectively. Monoline, MRX Partners, Monoline Rx, Monoline II, and Monoline III are referred to herein collectively as the "Monoline Entities" and each individually a "Monoline Entity". Bratton Capital Management, L.P. ("Bratton Capital Management") is the manager of MRX Partners and general partner of each of the other Monoline Entities. Bratton Capital, Inc. ("Bratton") is the general partner of Bratton Capital Management. The Reporting Person, Douglas K. Bratton, is the sole director and President of Bratton and has voting and investment power over all shares held by the Monoline Entities. F3 · ownership.nature: Bratton Capital Management, Bratton, and Mr. Bratton may each be deemed to own beneficially all shares owned by the Monoline Entities, and Bratton and Mr. Bratton may be deemed to beneficially own all shares held by Monosol. Each such entity and Mr. Bratton disclaims beneficial ownership of the reported securities except to the extent of its or his respective pecuniary interest therein. F8 · ownership.nature: These securities are beneficially owned by MRX Partners. Read SEC document
March 12, 2021 Filed Mar 16, 2021 20:20 UTC	Aquestive Therapeutics, Inc. AQST · Entity 5276	OtherCommon Stock	40,404	$0.00	$0.00	Disclosure SEC source: 0001214659-21-003203 · marketforms-51911.xml · nonDerivative · entry 4 BRATTON DOUGLAS K · CIK 0001281933 · 10% owner MonoLine Partners, L.P. · CIK 0001747211 · 10% owner MonoLine RX, L.P. · CIK 0001410626 · 10% owner MonoLine RX II, L.P. · CIK 0001410625 · 10% owner MonoLine RX III, L.P. · CIK 0001747169 · 10% owner MonoSol Rx Genpar, L.P. · CIK 0001747548 · 10% owner MRX Partners, LLC · CIK 0001746904 · 10% owner Bratton Capital Inc. · CIK 0001723783 · 10% owner Bratton Capital Management, L.P. · CIK 0001723787 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 47,051 F1 · kind: Pro rata distribution for no consideration of shares of common stock of the Issuer ("Common Stock") by the applicable MonoLine Entity or Monosol (each as defined below), as indicated in the respective footnotes. F3 · ownership.nature: Bratton Capital Management, Bratton, and Mr. Bratton may each be deemed to own beneficially all shares owned by the Monoline Entities, and Bratton and Mr. Bratton may be deemed to beneficially own all shares held by Monosol. Each such entity and Mr. Bratton disclaims beneficial ownership of the reported securities except to the extent of its or his respective pecuniary interest therein. F7 · ownership.nature: These securities are beneficially owned by MonoSol Rx Genpar, L.P. ("Monosol"). Bratton is the general partner of Monosol. The Reporting Person, Douglas K. Bratton, is the sole director and President of Bratton and has voting and investment power over all shares held by Monosol. Read SEC document
March 12, 2021 Filed Mar 16, 2021 20:20 UTC	Aquestive Therapeutics, Inc. AQST · Entity 5276	OtherCommon Stock	97,598	$0.00	$0.00	Disclosure SEC source: 0001214659-21-003203 · marketforms-51911.xml · nonDerivative · entry 3 BRATTON DOUGLAS K · CIK 0001281933 · 10% owner MonoLine Partners, L.P. · CIK 0001747211 · 10% owner MonoLine RX, L.P. · CIK 0001410626 · 10% owner MonoLine RX II, L.P. · CIK 0001410625 · 10% owner MonoLine RX III, L.P. · CIK 0001747169 · 10% owner MonoSol Rx Genpar, L.P. · CIK 0001747548 · 10% owner MRX Partners, LLC · CIK 0001746904 · 10% owner Bratton Capital Inc. · CIK 0001723783 · 10% owner Bratton Capital Management, L.P. · CIK 0001723787 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 2,657,943 F1 · kind: Pro rata distribution for no consideration of shares of common stock of the Issuer ("Common Stock") by the applicable MonoLine Entity or Monosol (each as defined below), as indicated in the respective footnotes. F2 · ownership.nature: These securities are owned, as indicated, by MonoLine Partners, L.P. ("MonoLine"), MRX Partners, LLC ("MRX Partners"), MonoLine Rx, L.P. ("Monoline Rx"), MonoLine Rx II, L.P. ("Monoline II"), and MonoLine Rx III, L.P. ("Monoline III"), respectively. Monoline, MRX Partners, Monoline Rx, Monoline II, and Monoline III are referred to herein collectively as the "Monoline Entities" and each individually a "Monoline Entity". Bratton Capital Management, L.P. ("Bratton Capital Management") is the manager of MRX Partners and general partner of each of the other Monoline Entities. Bratton Capital, Inc. ("Bratton") is the general partner of Bratton Capital Management. The Reporting Person, Douglas K. Bratton, is the sole director and President of Bratton and has voting and investment power over all shares held by the Monoline Entities. F3 · ownership.nature: Bratton Capital Management, Bratton, and Mr. Bratton may each be deemed to own beneficially all shares owned by the Monoline Entities, and Bratton and Mr. Bratton may be deemed to beneficially own all shares held by Monosol. Each such entity and Mr. Bratton disclaims beneficial ownership of the reported securities except to the extent of its or his respective pecuniary interest therein. F6 · ownership.nature: These securities are beneficially owned by Monoline III. Read SEC document
March 12, 2021 Filed Mar 16, 2021 20:20 UTC	Aquestive Therapeutics, Inc. AQST · Entity 5276	OtherCommon Stock	564,160	$0.00	$0.00	Disclosure SEC source: 0001214659-21-003203 · marketforms-51911.xml · nonDerivative · entry 2 BRATTON DOUGLAS K · CIK 0001281933 · 10% owner MonoLine Partners, L.P. · CIK 0001747211 · 10% owner MonoLine RX, L.P. · CIK 0001410626 · 10% owner MonoLine RX II, L.P. · CIK 0001410625 · 10% owner MonoLine RX III, L.P. · CIK 0001747169 · 10% owner MonoSol Rx Genpar, L.P. · CIK 0001747548 · 10% owner MRX Partners, LLC · CIK 0001746904 · 10% owner Bratton Capital Inc. · CIK 0001723783 · 10% owner Bratton Capital Management, L.P. · CIK 0001723787 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 3,468,747 F1 · kind: Pro rata distribution for no consideration of shares of common stock of the Issuer ("Common Stock") by the applicable MonoLine Entity or Monosol (each as defined below), as indicated in the respective footnotes. F2 · ownership.nature: These securities are owned, as indicated, by MonoLine Partners, L.P. ("MonoLine"), MRX Partners, LLC ("MRX Partners"), MonoLine Rx, L.P. ("Monoline Rx"), MonoLine Rx II, L.P. ("Monoline II"), and MonoLine Rx III, L.P. ("Monoline III"), respectively. Monoline, MRX Partners, Monoline Rx, Monoline II, and Monoline III are referred to herein collectively as the "Monoline Entities" and each individually a "Monoline Entity". Bratton Capital Management, L.P. ("Bratton Capital Management") is the manager of MRX Partners and general partner of each of the other Monoline Entities. Bratton Capital, Inc. ("Bratton") is the general partner of Bratton Capital Management. The Reporting Person, Douglas K. Bratton, is the sole director and President of Bratton and has voting and investment power over all shares held by the Monoline Entities. F3 · ownership.nature: Bratton Capital Management, Bratton, and Mr. Bratton may each be deemed to own beneficially all shares owned by the Monoline Entities, and Bratton and Mr. Bratton may be deemed to beneficially own all shares held by Monosol. Each such entity and Mr. Bratton disclaims beneficial ownership of the reported securities except to the extent of its or his respective pecuniary interest therein. F5 · ownership.nature: These securities are beneficially owned by Monoline II. Read SEC document
March 12, 2021 Filed Mar 16, 2021 20:20 UTC	Aquestive Therapeutics, Inc. AQST · Entity 5276	OtherCommon Stock	524,675	$0.00	$0.00	Disclosure SEC source: 0001214659-21-003203 · marketforms-51911.xml · nonDerivative · entry 1 BRATTON DOUGLAS K · CIK 0001281933 · 10% owner MonoLine Partners, L.P. · CIK 0001747211 · 10% owner MonoLine RX, L.P. · CIK 0001410626 · 10% owner MonoLine RX II, L.P. · CIK 0001410625 · 10% owner MonoLine RX III, L.P. · CIK 0001747169 · 10% owner MonoSol Rx Genpar, L.P. · CIK 0001747548 · 10% owner MRX Partners, LLC · CIK 0001746904 · 10% owner Bratton Capital Inc. · CIK 0001723783 · 10% owner Bratton Capital Management, L.P. · CIK 0001723787 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 1,688,639 F1 · kind: Pro rata distribution for no consideration of shares of common stock of the Issuer ("Common Stock") by the applicable MonoLine Entity or Monosol (each as defined below), as indicated in the respective footnotes. F2 · ownership.nature: These securities are owned, as indicated, by MonoLine Partners, L.P. ("MonoLine"), MRX Partners, LLC ("MRX Partners"), MonoLine Rx, L.P. ("Monoline Rx"), MonoLine Rx II, L.P. ("Monoline II"), and MonoLine Rx III, L.P. ("Monoline III"), respectively. Monoline, MRX Partners, Monoline Rx, Monoline II, and Monoline III are referred to herein collectively as the "Monoline Entities" and each individually a "Monoline Entity". Bratton Capital Management, L.P. ("Bratton Capital Management") is the manager of MRX Partners and general partner of each of the other Monoline Entities. Bratton Capital, Inc. ("Bratton") is the general partner of Bratton Capital Management. The Reporting Person, Douglas K. Bratton, is the sole director and President of Bratton and has voting and investment power over all shares held by the Monoline Entities. F3 · ownership.nature: Bratton Capital Management, Bratton, and Mr. Bratton may each be deemed to own beneficially all shares owned by the Monoline Entities, and Bratton and Mr. Bratton may be deemed to beneficially own all shares held by Monosol. Each such entity and Mr. Bratton disclaims beneficial ownership of the reported securities except to the extent of its or his respective pecuniary interest therein. F4 · ownership.nature: These securities are beneficially owned by Monoline Rx. Read SEC document
March 09, 2021 Filed Mar 16, 2021 20:20 UTC	Aquestive Therapeutics, Inc. AQST · Entity 5276	GiftCommon Stock	62,500	$0.00	$0.00	Disclosure SEC source: 0001214659-21-003203 · marketforms-51911.xml · nonDerivative · entry 7 BRATTON DOUGLAS K · CIK 0001281933 · 10% owner MonoLine Partners, L.P. · CIK 0001747211 · 10% owner MonoLine RX, L.P. · CIK 0001410626 · 10% owner MonoLine RX II, L.P. · CIK 0001410625 · 10% owner MonoLine RX III, L.P. · CIK 0001747169 · 10% owner MonoSol Rx Genpar, L.P. · CIK 0001747548 · 10% owner MRX Partners, LLC · CIK 0001746904 · 10% owner Bratton Capital Inc. · CIK 0001723783 · 10% owner Bratton Capital Management, L.P. · CIK 0001723787 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,585 F11 · kind: Gift of shares of Common Stock to charitable organization. F12 · balance_after: Following the transactions reported on this Form 4, the Reporting Persons as listed in this Form 4 are the beneficial owners in the aggregate of 10,060,657 shares of Common Stock for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, representing a 27.8% ownership interest in the Issuer based on total shares outstanding of 36,213,969 as of March 5, 2021, such shares outstanding as reported in the Issuer's Annual Report on Form 10-K for the fiscal year ended December 31, 2020. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.